Protea Biosciences Group Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Protea Biosciences Group Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7571
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Protea Biosciences Group Inc (Protea) is a biotechnology company that develops mass spectometry solutions. The company offers technology for identification, characterization, and quantitation of biologically-important molecules for pharmaceutical development, research, and diagnostic applications. Its products include functionalized pipette tips and plates, gel protein separation and recovery, protein sample preparation, amplus HPLC columns and mass spectrometry standards, among others. Protea’s services include bioanalytical services and mass spec imaging services. The company’s bioanalytical services include biomarker discovery, advanced proteomics and protein, biotherapeutic characterization and peptide quantitation, among others. It also provides label free imaging, translational, and drug and metabolite distribution. The company serves pharmaceutical, clinical, academic and industrial research. Protea is headquartered in Morgantown, West Virginia, the US.

Protea Biosciences Group Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Protea Biosciences Group Inc, Medical Devices Deals, 2012 to YTD 2018 10
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Protea Biosciences Enters into Co-Marketing Agreement with Proteos 12
Protea Biosciences Enters into Agreement with Agilent Technologies 13
Protea Biosciences Enters Into Research Agreement With Virginia Commonwealth University For Molecular Imaging Techniques 14
Waters Enters Into Co-Marketing Agreement With Protea Biosciences Group For LASEI DP-1000 15
Protea Biosciences Group Enters Into Co-Development Agreement With Oak Ridge National Lab 16
Licensing Agreements 17
Protea Biosciences Enters into License Agreement with George Washington University 17
Equity Offering 18
Protea Biosciences Files Registration Statement to Raise up to USD17.3 Million in Public Offering of Shares 18
Protea Biosciences Group Raises USD0.6 Million in Private Placement 19
Protea Biosciences Raises USD0.98 Million in Public Offering of Units 20
Protea Biosciences Raises USD2.53 Million in Public Offering of Units 21
Protea Biosciences Group Completes Private Placement Of Shares For US$0.7 Million 22
Protea Biosciences Completes Private Placement Of Shares For US$0.5 Million 23
Debt Offering 24
Protea Biosciences Raises USD0.1 Million in Private Placement of Debentures 24
Protea Biosciences Raises USD1.61 Million in Private Placement of Debentures 25
Protea Biosciences Raises USD2 Million in Private Placement of Debentures 26
Protea Biosciences Group Completes Private Placement Of Debt Securities For US$0.3 Million 27
Asset Transactions 28
Purdue University Acquires LAESI DP-1000 Instrument System from Protea Biosciences 28
Princeton University Acquires LAESI DP-1000 Instrument System from Protea Biosciences 29
Acquisition 30
Protea Biosciences to Acquire vivoPharm for USD11.2 Million 30
AzurRx BioPharma Acquires ProteaBio Europe for USD7 Million 32
Protea Biosciences Group Inc – Key Competitors 34
Protea Biosciences Group Inc – Key Employees 35
Protea Biosciences Group Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
Apr 18, 2017: Protea Announces 2016 Year End Results 37
Product News 38
Jun 21, 2017: Protea introduces new molecular imaging technology 38
Other Significant Developments 39
Jul 12, 2017: Protea Announces New Test Methods for Therapeutic Antibodies 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Key Facts 2
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Protea Biosciences Group Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Protea Biosciences Group Inc, Medical Devices Deals, 2012 to YTD 2018 10
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Protea Biosciences Enters into Co-Marketing Agreement with Proteos 12
Protea Biosciences Enters into Agreement with Agilent Technologies 13
Protea Biosciences Enters Into Research Agreement With Virginia Commonwealth University For Molecular Imaging Techniques 14
Waters Enters Into Co-Marketing Agreement With Protea Biosciences Group For LASEI DP-1000 15
Protea Biosciences Group Enters Into Co-Development Agreement With Oak Ridge National Lab 16
Protea Biosciences Enters into License Agreement with George Washington University 17
Protea Biosciences Files Registration Statement to Raise up to USD17.3 Million in Public Offering of Shares 18
Protea Biosciences Group Raises USD0.6 Million in Private Placement 19
Protea Biosciences Raises USD0.98 Million in Public Offering of Units 20
Protea Biosciences Raises USD2.53 Million in Public Offering of Units 21
Protea Biosciences Group Completes Private Placement Of Shares For US$0.7 Million 22
Protea Biosciences Completes Private Placement Of Shares For US$0.5 Million 23
Protea Biosciences Raises USD0.1 Million in Private Placement of Debentures 24
Protea Biosciences Raises USD1.61 Million in Private Placement of Debentures 25
Protea Biosciences Raises USD2 Million in Private Placement of Debentures 26
Protea Biosciences Group Completes Private Placement Of Debt Securities For US$0.3 Million 27
Purdue University Acquires LAESI DP-1000 Instrument System from Protea Biosciences 28
Princeton University Acquires LAESI DP-1000 Instrument System from Protea Biosciences 29
Protea Biosciences to Acquire vivoPharm for USD11.2 Million 30
AzurRx BioPharma Acquires ProteaBio Europe for USD7 Million 32
Protea Biosciences Group Inc, Key Competitors 34
Protea Biosciences Group Inc, Key Employees 35
Protea Biosciences Group Inc, Subsidiaries 36

List of Figures
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Protea Biosciences Group Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Protea Biosciences Group Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Vietnam Joint Stock Commercial Bank for Industry and Trade:企業の戦略・SWOT・財務情報
    Vietnam Joint Stock Commercial Bank for Industry and Trade - Strategy, SWOT and Corporate Finance Report Summary Vietnam Joint Stock Commercial Bank for Industry and Trade - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the …
  • FLSmidth & Co AS (FLS):企業の財務・戦略的SWOT分析
    FLSmidth & Co AS (FLS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Innovative Med Concepts LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Innovative Med Concepts LLC (Innovative Med Concepts) is a biotech company that develops novel treatments for the treatment of fibromyalgia and other related syndromes. The company’s pipeline products include NRP-1, a throat spray which is used to treat viral pharyngitis that provides relief …
  • ESSA Pharma Inc (EPI)-製薬・医療分野:企業M&A・提携分析
    Summary Essa Pharma Inc (Essa Pharma) is a clinical-stage pharmaceutical company that carries out the development of small molecule drugs for the treatment castration-resistant prostate cancer (CRPC). The company’s lead product candidate, EPI-506, disrupts androgen receptor (AR) transcriptional acti …
  • Famous Dave’s of America, Inc.:企業の戦略・SWOT・財務情報
    Famous Dave's of America, Inc. - Strategy, SWOT and Corporate Finance Report Summary Famous Dave's of America, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Ameren Corporation (AEE)-エネルギー分野:企業M&A・提携分析
    Summary Ameren Corporation (Ameren) is a public utility holding company that generates, transmits and distributes electricity; and transmits and distributes natural gas through its subsidiaries. The company generates electricity through varied energy sources such as coal, nuclear, hydro, solar, natu …
  • Mercury General Corporation:戦略・SWOT・企業財務分析
    Mercury General Corporation - Strategy, SWOT and Corporate Finance Report Summary Mercury General Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Pearl Polymers Ltd.:企業の戦略・SWOT・財務情報
    Pearl Polymers Ltd. - Strategy, SWOT and Corporate Finance Report Summary Pearl Polymers Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • STRABAG International GmbH:企業の戦略的SWOT分析
    STRABAG International GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Carbery Group:企業の戦略・SWOT・財務情報
    Carbery Group - Strategy, SWOT and Corporate Finance Report Summary Carbery Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Cimarex Energy Co (XEC):石油・ガス:M&Aディール及び事業提携情報
    Summary Cimarex Energy Co (Cimarax) is an independent upstream oil and natural gas company. It carries out the exploration and production of crude oil, natural gas and natural gas liquids (NGLs). The company’s operations are concentrated in two main areas namely the Mid-Continent region consisting o …
  • Decibel Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Decibel Therapeutics Inc (Decibel) is a hearing company that offers discovery, development and commercialization of new medicines for the treatment of hearing disorders. The company offer drugs for pediatric cancer and cystic fibrosis patients who experience ototoxicity or hearing loss. It p …
  • Athenex Inc (ATNX):製薬・医療:M&Aディール及び事業提携情報
    Summary Athenex Inc (Athenex), formerly Kinex Pharmaceuticals LLC, is a biopharmaceutical company focused on the discovery, development and commercialization novel medicines and cell therapies for the treatment of cancers. The company’s orascovery products candidates include oral formulations of pac …
  • Accugenomics Inc:企業の製品パイプライン分析
    Summary Accugenomics Inc (Accugenomics) is a developer of oncology molecular diagnostics. The company develops and markets gene expression tests to diagnose and monitor cancer treatment. It offers gene expression tests including lung cancer risk test, standardized BCR-ABL molecular diagnostics test …
  • CS Wind Corp (112610):企業の財務・戦略的SWOT分析
    Summary CS Wind Corp (CS Wind) formerly Choong San Corp, is a global wind tower company that manufactures and distributes aluminum platforms used for wind power generation towers. The company’s products include transition piece, wind tower, tower internal parts, oil and gas pipes, and plant equipmen …
  • EOS imaging SA (EOSI):企業の財務・戦略的SWOT分析
    EOS imaging SA (EOSI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Currence Holding B.V.:企業の戦略・SWOT・財務分析
    Currence Holding B.V. - Strategy, SWOT and Corporate Finance Report Summary Currence Holding B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • USV Pvt Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary USV Pvt Ltd (USV) is a healthcare company that offers pharmaceutical products. The company’s products include active pharmaceutical ingredients, biosimilars, injectables, ophthalmics, peptides and solid orals. Its biosimilars products comprise PEG-filgrastim, teriparatide, somatropin, filgra …
  • Petrol dd Ljubljana (PETG):企業の財務・戦略的SWOT分析
    Petrol dd Ljubljana (PETG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • TriMas Corporation:企業のM&A・事業提携・投資動向
    TriMas Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's TriMas Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆